We are live on
!
Find out more
NTC
North Tide Capital Portfolio holdings
AUM
$469M
1-Year Est. Return
6.57%
This Fund
S&P 500
This Quarter
Est. Return
+8.75%
1 Year Est. Return
+6.57%
3 Year Est. Return
+14.81%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
+$243M
(+20%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
8.87%
Top 10 Holdings %
Top 10 Hldgs %
63.17%
Holding
29
New
5
Increased
9
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$63.8M |
| 2 |
Edwards Lifesciences
EW
|
+$48.8M |
| 3 |
SVU
SUPERVALU Inc.
SVU
|
+$47.9M |
| 4 |
VVUS
Vivus Inc
VVUS
|
+$46.3M |
| 5 |
Boston Scientific
BSX
|
+$44.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$82.3M |
| 2 |
AGN
Allergan Inc
AGN
|
+$77.8M |
| 3 |
Elevance Health
ELV
|
+$25.8M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$25M |
| 5 |
Viatris
VTRS
|
+$24.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.38% |
| 2 | Consumer Discretionary | 4.51% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GHDX
26
DELISTED
Genomic Health, Inc.
GHDX
| $8.22M | 0.57% |
300,000
+200,000
| +200% | +$5.32M |
|
|
27
Viatris
VTRS
$20.1B
| – | – |
-500,000
| Closed | -$24.4M |
|
|
AGN
28
DELISTED
Allergan plc
AGN
| – | – |
-400,000
| Closed | -$82.3M |
|
|
AH
29
DELISTED
Accretive Health
AH
| – | – |
-2,000,000
| Closed | -$16M |
|
Similar funds
SD
DG
NBC
JWM
JPCCM
MCL
GIIO
FC
North Tide Capital's Q2 2014 Portfolio in Review
As of Q2 2014, North Tide Capital held 29 positions worth $1.43B, up 20% from $1.19B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
North Tide Capital deployed $127M of net new capital in Q2 2014, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Bausch Health: 500,000 shares worth $63.1M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Allergan Inc, an estimated $77.8M trimmed.
- North Tide Capital's largest Q2 2014 buy was Bausch Health: 500,000 shares worth $63.1M.
- North Tide Capital added most to SUPERVALU Inc. in Q2 2014, an estimated $47.9M increase.
- North Tide Capital's biggest Q2 2014 reduction was Allergan Inc, cutting an estimated $77.8M.
- North Tide Capital fully exited Allergan plc in Q2 2014, selling an estimated $82.3M.
- North Tide Capital's ten largest holdings make up 63% of its $1.43B portfolio in Q2 2014.
- North Tide Capital opened 5 new positions and closed 3 in Q2 2014.
- North Tide Capital's portfolio value rose 20% quarter-over-quarter to $1.43B.
Based on North Tide Capital's 13F filing for Q2 2014, filed 14 Aug 2014.